EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Myeloablation Followed by Hematopoietic Stem Cell Transplantation and Long‐Term Normalization of Systemic Sclerosis Molecular Signatures

Nancy Wareing iD, Xuan Wang, Lynette Keyes-Elstein, Ellen A Goldmuntz, Marka A Lyons, Peter McSweeney, Daniel E Furst iD, Richard A Nash, Leslie J Crofford, Beverly Welch, Ashley Pinckney, Maureen D Mayes iD und 2 weitere

Arthritis & Rheumatology · 2024

DOI: 10.1002/art.42847 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Arthritis & Rheumatology, 2024. Verfasst von Nancy Wareing und 13 weiteren Autor:innen. Beteiligte Einrichtung: UTHealth Houston McGovern Medical School, Houston, Texas. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Myeloablative Agonists, Scleroderma, Systemic, Gene Expression Profiling. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, The Scleroderma: Cyclophosphamide or Transplantation (SCOT), NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

In the randomized Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial, myeloablation, followed by hematopoietic stem cell transplantation (HSCT), led to the normalization of systemic sclerosis (SSc) peripheral blood cell (PBC) gene expression signature at the 26‐month visit. Herein, we examined long‐term molecular changes ensuing 54 months after randomization for individuals receiving an HSCT or 12 months of intravenous cyclophosphamide (CYC).

Methods

Global PBC transcript studies were performed in study participants at pretreatment baseline and at 38 months and 54 months after randomization, as well as in healthy controls using Illumina HT‐12 arrays.

Results

Thirty (HSCT = 19 and CYC = 11) participants had 38‐month samples available, and 26 (HSCT = 16 and CYC = 11) had 54‐month samples available. In the paired comparison to baseline, a significant down‐regulation of interferon modules and an up‐regulation of cytotoxic/natural killer module were observed at the 38‐month and 54‐month visits in the HSCT arm, indicating a long‐term normalization of baseline SSc gene expression signature. No differentially expressed modules were detected in the CYC arm. In comparison to samples from healthy controls, 38‐month visit samples in the HSCT arm showed an up‐regulation of B cell and plasmablast modules and a down‐regulation of myeloid and inflammation modules. Importantly, 54‐month HSCT samples did not show any differentially expressed modules compared to healthy control samples, suggesting completion of immune reconstitution. Participants in the CYC arm continued to show an SSc transcript signature in comparison to controls at both time points.

Conclusion

Paralleling the observed clinical benefit, HSCT leads to durable long‐term normalization of the molecular signature in SSc, with completion of immune resetting to 54 months after HSCT. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationMyeloablative AgonistsScleroderma, SystemicGene Expression ProfilingAdultFemaleHumansMaleMiddle AgedCyclophosphamideDown-RegulationImmunosuppressive AgentsTranscriptomeTransplantation ConditioningCombined Modality Therapy

Substanzen

CyclophosphamideImmunosuppressive AgentsMyeloablative Agonists

Autor:innen und Institutionen

  • UTHealth Houston McGovern Medical School, Houston, Texas.
  • Baylor Institute for Immunology Research, Dallas, Texas.
  • Rho Inc., Durham, North Carolina.
  • National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland.
  • Colorado Blood Cancer Institute, Denver.
  • University of California Los Angeles, and University of Washington, Seattle.

ORCID-Profile: Nancy Wareing, Daniel E Furst, Maureen D Mayes, Keith M Sullivan, Shervin Assassi

Förderung

  • NIAID NIH HHS
  • The Scleroderma: Cyclophosphamide or Transplantation (SCOT)
  • NIAMS NIH HHS
  • NIH HHS
  • Karen Brown Scleroderma Foundation
  • National Institute of Allergy and Infectious Diseases
  • Department of Defense
  • NIH

Zitieren

APA

Wareing, N., Wang, X., Keyes-Elstein, L., Goldmuntz, E. A., Lyons, M. A., McSweeney, P., Furst, D. E., Nash, R. A., Crofford, L. J., Welch, B., Pinckney, A., Mayes, M. D., Sullivan, K. M., & Assassi, S. (2024). Myeloablation Followed by Hematopoietic Stem Cell Transplantation and Long‐Term Normalization of Systemic Sclerosis Molecular Signatures. Arthritis & Rheumatology. https://doi.org/10.1002/art.42847

Vancouver

Wareing N, Wang X, Keyes-Elstein L, Goldmuntz EA, Lyons MA, McSweeney P, et al. Myeloablation Followed by Hematopoietic Stem Cell Transplantation and Long‐Term Normalization of Systemic Sclerosis Molecular Signatures. Arthritis & Rheumatology. 2024. doi:10.1002/art.42847

BibTeX
@article{Wareing2024,
  author = {Wareing, Nancy and Wang, Xuan and Keyes-Elstein, Lynette and Goldmuntz, Ellen A and Lyons, Marka A and McSweeney, Peter and Furst, Daniel E and Nash, Richard A and Crofford, Leslie J and Welch, Beverly and Pinckney, Ashley and Mayes, Maureen D and Sullivan, Keith M and Assassi, Shervin},
  title = {Myeloablation Followed by Hematopoietic Stem Cell Transplantation and Long‐Term Normalization of Systemic Sclerosis Molecular Signatures},
  journal = {Arthritis & Rheumatology},
  year = {2024},
  doi = {10.1002/art.42847}
}
Kostenlos starten →